This book presents a comprehensive update of the latest findings in oncogenetics. It also investigates the relevance of preclinical models with respect to clinical cancer prevention (primary and secondary) for major cancer types such as breast, skin, lung, prostate and colon cancer. All contributions have been written by internationally recognised experts in the field.
Indice testuale
From the contents: Genetic susceptibility, predicting risk and preventing cancer.- Novel approaches to identify low penetrance cancer susceptibility genes using mouse models.- Development of novel selective cell ablation in the mammary gland and brain to study cell-cell interactions and chemoprevention.- Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs.- Preclinical models for chemoprevention of colon cancer.- New cancer biomarkers deriving from the NCI early detection research.- Tamoxifen's impact as a preventive agent in clinical practice.- Aromatase inhibitors in prevention.- HRT opposed to low dose Tamoxifen.- Is mammography screening for breast cancer really not justifiable?- How reliable is the evidence for screening mammography.- Breast cancer screening policies around the world.- Skin cancer chemoprevention.- Chemoprevention of non-melanoma skin cancer.- Chemoprevention of lung cancer.- Key issues in lung cancer chemoprevention trials of new agents.
